Original Article
Is Pentraxin 3 a New Cardiovascular Risk Marker in Polycystic Ovary Syndrome?Sari U.a · Kaygusuz I.b · Kafali H.caDepartment of Obstetrics and Gynecology, Acibadem Levent Medical Center, Istanbul, bDepartment of Obstetrics and Gynecology, Turgut Ozal University Medical School, and cDepartment of Obstetrics and Gynecology, Gazi University Medical School, Ankara, Turkey
|
|
Gynecol Obstet Invest 2014;78:173-178
Do you have an account?
To view the fulltext, please log in
To view the pdf, please log in
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: May 27, 2013
Accepted: May 18, 2014
Published online: July 09, 2014
Issue release date: September 2014
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Background/Aims: Polycystic ovary syndrome (PCOS) patients have an increased rate of subclinical inflammation, which plays a role in the pathogenesis of atherosclerosis. Pentraxin 3 (PTX3) is an inflammatory mediator which belongs to the same family as the well-established cardiovascular biomarker C-reactive protein (CRP). The present study was performed to investigate plasma PTX3 levels in patients with PCOS and to determine the relationship between PTX3 and other known cardiovascular risk factors. Methods: 40 patients with PCOS and 40 age- and BMI-matched healthy controls were included in the study. The groups were divided into subgroups according to BMI. Insulin resistance indexes, lipid profile, CRP and PTX3 levels were analyzed. Results: There was no difference for insulin resistance indexes and lipid profile between the PCOS and control groups. CRP levels were significantly higher in obese PCOS and control subjects than in lean subjects, whereas no difference in PTX3 concentrations was observed between subgroups. Conclusion: PTX3 and CRP levels were similar in the PCOS group compared with the non-PCOS control group.
© 2014 S. Karger AG, Basel
Related Articles:
References
- Legro RS, Strauss JF: Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002;78:569-576.
- Homburg R: Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008;2:261-274.
- Ovalle F, Azziz R: Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-1105.
- Dahlgren E, Janson PO: Polycystic ovary syndrome: long-term metabolic consequences. Int J Gynaecol Obstet 1994;44:3-8.
- Shen ZQ, Zhu HT, Lin JF: Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465-467.
- Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS: Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1357-1363.
- Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, et al: Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-2421.
- Aydoğdu A, Tasci I, Tapan S, Sonmez A, Aydogan U, Akbulut H, et al: Women with polycystic ovary syndrome have increased plasma chitotriosidase activity: a pathophysiological link between inflammation and impaired insulin sensitivity? Exp Clin Endocrinol Diabetes 2012;120:261-265.
- Mantovani A, Garlanda C, Bottazzi B: Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003;21:43-47.
- Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-366.
- Bottazzi B, Doni A, Garlanda C, Mantovani A: An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010;28:157-183.
- Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GH: Production of the long pentraxin PTX3 in advanced atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2002;22:10-14.
- Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al: Establishment of a high-sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-167.
- Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-2354.
- Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al: Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81.
- Aydoğdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Meric C, et al: High plasma level of long pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2012;28:722-725.
- Iftikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S, et al: Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012;70:74-80.
- Venn AJ, Thomson RJ, Schmidt MD, Cleland VJ, Curry BA, Gennat HC, et al: Overweight and obesity from childhood to adulthood: a follow-up of participants in the 1985 Australian Schools Health and Fitness Survey. Med J Aust 2007;186:458-460.
- Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997;96:2520-2525.
- Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS: The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299-4306.
- Karakurt F, Carlioglu A, Kaygusuz I, Gumus II, Uz B, Akdeniz D: Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet 2014;289:135-140.
- Gözdemir E, Kaygusuz I, Kafali H: Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome? Gynecol Obstet Invest 2013;75:196-202.
- Amador N, Espinoza G, Guizar JM, Gonzalez M, Alpizar M: Comparison of HOMA-IR with the minimal model for measuring insulin sensitivity in polycystic ovary syndrome (in Spanish). Rev Invest Clin 2001;53:407-412.
- Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
- Kazerooni T, Dehghan-Kooshkghazi M: Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003;17:51-56.
- Siebert TI, Viola MI, Steyn DW, Kruger TF: Is metformin indicated as primary ovulation-induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol Obstet Invest 2012;73:304-313.
- Samy N, Hashim M, Sayed M, Said M: Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009;26:163-170.
- Verit F: High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet 2010;281:1009-1014.
Article / Publication Details
First-Page Preview
Received: May 27, 2013
Accepted: May 18, 2014
Published online: July 09, 2014
Issue release date: September 2014
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID